CeMM Adjunct Principal Investigator
Thijn Brummelkamp uses genetic approaches to identify genes that play a role in human disease. His primary interests are cancer research, infectious disease and drug action.
Brummelkamp has developed technologies to accelerate genetic analysis of cultured mammalian cells. A 'stable RNA interference' process, which he and his colleagues first described, is now widely used to manipulate and study gene function in mammalian cells. Brummelkamp has used stable RNA interference to inhibit thousands of human genes, in order to find specific genes that play a role in human disease. More recently he has developed an approach for haploid genetic screens in human cells using insertional mutagenesis. He has used this approach to identify host factors used by a variety of pathogens.
Thijn Brummelkamp received his MS in biology from the Free University, Amsterdam, in 1998. He did his graduate research at The Netherlands Cancer Institute in the laboratory of Rene Bernards and received his PhD cum laude from Utrecht University in 2003. Thijn was appointed as a Whitehead Fellow in 2004 to initiate his independent research program at the Whitehead Institute for Biomedical Research in Cambridge, USA. In 2011 his laboratory moved to the Netherlands Cancer Institute and he became an Adjunct PI at CeMM. For his studies he received the Antoni van Leeuwenhoek Award (2003), The Annual NVBMB Award (2004, Dutch Association for Biochemistry and Molecular Biology), he was chosen as one of the world’s top 35 Young Innovators by MIT’s technology Review magazine (2005), he received the Kimmel Scholar Award (2006) and an ERC starting grant in 2012.